Shares of Genomic Health Inc. (NASDAQ:GHDX) rose 2.6% on Thursday . The stock traded as high as $28.92 and last traded at $28.64, with a volume of 68,468 shares changing hands. The stock had previously closed at $27.92.

GHDX has been the topic of several recent research reports. Leerink Swann reiterated a “buy” rating on shares of Genomic Health in a research report on Tuesday, June 21st. Canaccord Genuity upgraded shares of Genomic Health from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a research report on Wednesday, June 1st. Finally, Zacks Investment Research upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $33.50.

The company’s market cap is $953.14 million. The company’s 50-day moving average is $26.73 and its 200-day moving average is $27.05.

Genomic Health (NASDAQ:GHDX) last posted its earnings results on Wednesday, May 4th. The company reported ($0.19) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.24) by $0.05. The firm earned $80.89 million during the quarter, compared to the consensus estimate of $78.12 million. During the same period in the previous year, the company posted ($0.30) EPS. The firm’s revenue for the quarter was up 18.7% compared to the same quarter last year. Equities analysts forecast that Genomic Health Inc. will post ($0.45) earnings per share for the current year.

In other news, insider James J. Vaughn sold 1,997 shares of the company’s stock in a transaction dated Monday, June 6th. The shares were sold at an average price of $28.00, for a total value of $55,916.00. Following the sale, the insider now owns 34,076 shares of the company’s stock, valued at approximately $954,128. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 6th. The stock was sold at an average price of $26.64, for a total transaction of $133,200.00. Following the completion of the sale, the chief operating officer now directly owns 40,426 shares in the company, valued at approximately $1,076,948.64. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently modified their holdings of the company. Marshall Wace LLP bought a new position in shares of Genomic Health during the fourth quarter valued at about $6,097,000. Royce & Associates LLC increased its position in shares of Genomic Health by 90.0% in the fourth quarter. Royce & Associates LLC now owns 66,500 shares of the company’s stock valued at $2,341,000 after buying an additional 31,500 shares during the period. GSA Capital Partners LLP increased its position in shares of Genomic Health by 7.2% in the fourth quarter. GSA Capital Partners LLP now owns 112,260 shares of the company’s stock valued at $3,952,000 after buying an additional 7,512 shares during the period. EAM Investors LLC bought a new position in shares of Genomic Health during the fourth quarter valued at about $1,055,000. Finally, ProShare Advisors LLC increased its position in shares of Genomic Health by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 28,759 shares of the company’s stock valued at $1,012,000 after buying an additional 2,287 shares during the period.

Genomic Health, Inc is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.